Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- BioCryst Pharmaceuticals Inc (BCRX) reported a 34% year-over-year growth in ORLADEYO revenue for 2024, indicating strong market performance.
- The company achieved a non-GAAP operating profit of over $60 million, which was three times larger than planned, showcasing effective financial management.
- BioCryst Pharmaceuticals Inc (BCRX) is advancing its pipeline with promising clinical trials for BCX17725 for Netherton Syndrome and Avoralstat for Diabetic Macular Edema.
- The company is on track to file an NDA for ORLADEYO for pediatric use, expanding its market potential to children aged 2 to 11.
- BioCryst Pharmaceuticals Inc (BCRX) raised its ORLADEYO revenue guidance for 2025 to $535 million to $550 million, reflecting strong demand and favorable impacts from the Inflation Reduction Act for Medicare patients.
- The company faces uncertainty around future government funding for RAPIVAB, which could impact revenue streams.
- There is a potential headwind from foreign exchange rates, particularly affecting revenue from the European Union.
- BioCryst Pharmaceuticals Inc (BCRX) anticipates flat to slightly down revenue in Q1 2025 due to the reauthorization season and gross-to-net impacts.
- The company acknowledges that the Netherton Syndrome market is underdiagnosed, which could pose challenges in patient identification and market penetration.
- Despite the positive outlook, the company remains cautious about the variability in ex-US demand and the impact of distributor shipment timing on quarterly results.
Good day and welcome to the BioCryst fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to John Bluth, at BioCryst. Please go ahead.
Thanks, Drave. Good morning and welcome to BioCryst's fourth quarter 2024 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.
Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
